98%
921
2 minutes
20
Objective: This paper reports on the implementation and shows examples of the use of the ProTheRaMon framework for simulating the delivery of proton therapy treatment plans and range monitoring using positron emission tomography (PET). ProTheRaMon offers complete processing of proton therapy treatment plans, patient CT geometries, and intra-treatment PET imaging, taking into account therapy and imaging coordinate systems and activity decay during the PET imaging protocol specific to a given proton therapy facility. We present the ProTheRaMon framework and illustrate its potential use case and data processing steps for a patient treated at the Cyclotron Centre Bronowice (CCB) proton therapy center in Krakow, Poland.
Approach: The ProTheRaMon framework is based on GATE Monte Carlo software, the CASToR reconstruction package and in-house developed Python and bash scripts. The framework consists of five separated simulation and data processing steps, that can be further optimized according to the user's needs and specific settings of a given proton therapy facility and PET scanner design.
Main Results: ProTheRaMon is presented using example data from a patient treated at CCB and the J-PET scanner to demonstrate the application of the framework for proton therapy range monitoring. The output of each simulation and data processing stage is described and visualized.
Significance: We demonstrate that the ProTheRaMon simulation platform is a high-performance tool, capable of running on a computational cluster and suitable for multi-parameter studies, with databases consisting of large number of patients, as well as different PET scanner geometries and settings for range monitoring in a clinical environment. Due to its modular structure, the ProTheRaMon framework can be adjusted for different proton therapy centers and/or different PET detector geometries. It is available to the community via github.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ac944c | DOI Listing |
Rev Sci Instrum
September 2025
HUN-REN Centre for Energy Research, Budapest, Hungary.
A novel medium-current (up to 20 mA), low normalized beam emittance (<1 π mm mrad) electron cyclotron resonance microwave H+ ion source has been developed at the Center for Energy Research in Budapest, Hungary. This high-stability design targets an energy ripple below 1% while delivering a continuous or pulsed proton beam with adjustable pulse duration (0.1-10 ms) and frequency (0.
View Article and Find Full Text PDFInfect Drug Resist
August 2025
Department of Pharmacy, Mie University Hospital, Mie, Japan.
Background: The comparative effectiveness and potential impact of individual proton pump inhibitors (PPIs) on the development of infection (CDI) remain unclear. Additionally, there is insufficient evidence to support the use of probiotics for CDI prevention outside clinical trials. This study aimed to identify the PPIs that are most associated with CDI development and to determine whether probiotic co-administration can reduce this risk.
View Article and Find Full Text PDFHead Neck
September 2025
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Flap complications following maxillectomy, reconstruction, and adjuvant proton beam therapy (PBT) for primary maxillary and sinonasal malignancies are not well described.
Methods: This retrospective cohort study included consecutive patients treated between 2016 and 2023 from a single-institutional database.
Results: Thirteen patients were identified with a median follow-up of 26 months.
Pharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFOral Oncol
September 2025
Department of Radiation Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey. Electronic address: